FDA Grants Special Designations to Sangamo for Hemophilia Gene Therapies – Hemophilia News Today
|
FDA Grants Special Designations to Sangamo for Hemophilia Gene Therapies
Hemophilia News Today Two gene therapies from Sangamo Therapeutics for hemophilia A and B have been granted special regulatory designations by the U.S. Food and Drug Administration (FDA). Sangamo said in a press release that the FDA has granted orphan drug status to … |
